Naslov
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication - a randomised controlled trial

Autori
Bago, Josip ; Belošić Halle, Željka ; Strinić, Dean ; Kučišec, Nastja ; Jandrić, Dubravka ; Bevanda, Milenko ; Tomić, M. ; Bilić, Ante

Izvornik
Wiener Klinische Wochenschrift (0043-5325) 114 (2002), 12; 448-453

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
primary antibiotics resistance ; ranitidine bismuth citrate ; omeprazole

Sažetak
AIMS: To compare ranitidine bismuth citrate with omeprazole as to their efficacy to eradicate H. pylori in two different treatment schedules both consisting of a combination of either of above with two antibiotics for 1 week, and to relate these treatment results to primary antibiotic resistance. METHODS: 256 H. pylori positive patients with non-ulcer dyspepsia were randomised to one of the following four treatment groups: omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA) ; ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA) ; omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM) ; ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM). All drugs were given twice daily for one week. The patients were assessed for prevalence of H. pylori by CLO test, histology and culture on gastric biopsy samples obtained during upper gastrointestinal endoscopy before randomisation and 4-6 weeks after completion of therapy. Bacterial sensitivity to clarithromycin, metronidazole and amoxycillin was determined by E-test. RESULTS: On per-protocol analysis, overall eradication rates were 96% for RBCCA vs. 85% for OCA (p = 0.03), and 95% for RBCCM vs. 79% for OCM (p = 0.01). Amongst the 196 patients (77% of the entire study group) in whom antibiotic sensitivity testing was technically feasible, primary resistance was found in 8% for clarithromycin, in 33% for metronidazole, and in 0% for amoxycillin. Eradication of clarithromycin sensitive/resistant strains was 89%/40% for OCA (p = 0.0042) and 98%/80% for RBCCA (p = 0.0428). When strains were sensitive to both antibiotics, cure rates with OCM/RBCCM were 87%/96% respectively (p = 0.39), for strains resistant to clarithromycin only, eradication was achieved in 82% with OCM vs. 94% with RBCCM (p = 0.2), and in the case of metronidazole resistance in 85% with OCM vs. 94% with RBCCM (p = 0.09). CONCLUSIONS: Ranitidine bismuth citrate in combination with clarithromycin and either metronidazole or amoxycillin produced higher eradication rates than omeprazole co-administered with the same antibiotics. This appeared especially prominent in the subgroups with clarithromycin resistance without, however, reaching statistical significance. Efficacy of neither eradication regimen was influenced by metronidazole sensitivity to a significant degree.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Cilj ovog rada je usporediti efikasnost ranitidin bizmut citrata sa omeprazolom na efikasnost eradikacije H.pylori u dva različita tretmana koji sadrže kombnaciju jednog od njih sa dva antibiotika u trajanju od tjedan dana i povezati rezultate ovog istraživanja sa primarnom antibiotskom rezistencijom. 256 pacijenata pozitivnih na H.pylori sa ne-ulceroznom dispepsijom su randomizirani u jednu od 4 sljedećih grupa :omeprazol 20 mg + clarithromicin 500mg + amoxycillin 1000mg (OCA) ; ranitidin bizmut citrat 400 mg + clarithromycin 500mg + amoxycillin1000mg (RBCCA) ; omeprazol 20 mg + clarithromycin 500 mg + metronidazol 500 mg (OCM) ; ranitidin bizmut citrat 400mg + clarithromycin 500 mg + metronidazol 500 mg (RBCCM).Svi su lijekovi davani dva puta dnevno tijekom jednog tjedna. Pacijenti su testirani na H.pylori CLO testom. Histologija i kultura želučane biopsije je obavljena tijekom gornje gastrointestinalne biopsije prije randomizacije i 4-6 tjedana nakon završene terapije.Bakterijska osjetljivost na chlaritromycin, metronidazol i amoxycilin je određena E-testom.Per-protocol analizom cjelokupna stopa eradikacije je bila 96% za RBCCA prema 85% za OCA (p=0.03), 95% za RBCCM prema 79% za OCM (p=0.01).Između 196 pacijenata (77% od cijele grupe) u kojih je testiranje na osjetljivost bilo tehnički ostvarivo, primarna rezistencija je nađena u 8% za claritromycin, 33% za metronidazol i u 0% na amoxycillin.Eradikacija za clarithromycin osjetljive/rezistentne sojeve je bila 89/40% za OCA (p=0.0042) i 98/80% za RBCCA(p=0.0428).Kada su sojevi bili osjetljivi na oba antibiotika, stopa izlječenja sa OCM /RBCCM je bila 87/96% (p=0.39), za sojeve rezistentne samo na clarithromycin, eradikacija je postignuta u 82% sa OCM prema 94% sa RBCCM (p=0.2) i u slučaju rezistencije na metronidazol 85% sa OCM prema 94% sa RBCCM (p=0.09).Ranitidin bizmut citrat u kombinaciji sa clarithromycinom i metronidazolom ili amoxycillinom postigao je veću stopu eradikacije nego omeprazol u kombinaciji s istim antibioticima.To se posebno ističe u subgrupi sa rezistencijom na clarithromycin, iako bez značajne statističke razlike.Osjetljivost na metronidazol nije značajnije utjecala na efikasnost niti jednog od eradikacijskih postupaka.

POVEZANOST RADA